

Kunnen voorgeschreven cannabinoïden cannabis vervangen?

Nout Schukking, Pim van der Meer & Albert Batalla

[1] Schlag AK, Baldwin DS, Barnes M, Bazire S, Coathup R, Curran HV, et al. Medical cannabis in the UK: From principle to practice. *J Psychopharmacol.* 2020;34(9):931-7.

[2] Connor JP, Stjepanovic D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. *Nat Rev Dis Primers.* 2021;7(1):16.

[3] United Nations Office on Drugs and Crime. World drug report 2021. 2021;Vienna: United Nations Office on Drugs and Crime.

[4] EMCDDA. Cannabis policy: status and recent developments. EMCDDA Europa. Lisbon, Portugal: European Monitoring Centre for Drugs and Addiction, 2019.
https://www.emcdda.europa.eu/news/2019/who-recommends-rescheduling-of-cannabis_en. 2019.

[5] Trimbos Instituut. Nationale Drug Monitor 2022. 2023.

[6] Hazekamp A. The Trouble with CBD Oil. *Med Cannabis Cannabinoids.* 2018;1(1):65-72.

[7] Spindle TR, Sholler DJ, Cone EJ, Murphy TP, ElSohly M, Winecker RE, et al. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. *JAMA Netw Open.* 2022;5(7):e2223019.

[8] Millar SA, Stone NL, Yates AS, O' Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. *Front Pharmacol.* 2018;9:1365.

[9] Bureau voor Medicinale Cannabis ministerie van VWS. Medicinale Cannabis, Informatie voor apothekers en medische beroepsbeoefenaren. Via:
<https://www.cannabisbureau.nl/binaries/cannabisbureau/documenten/brochures/2018/02/26/informatie-voor-apothekers-en-medische-beroepsbeoefenaren/Informatie+voor+apothekers+en+medische+beroepsbeoefenaren+versie+november+2021.pdf>.

[10] Stichting Farmaceutische Kengetallen. Lichte daling verstrekkingen van medicinale cannabis. *Pharmaceutisch Weekblad.* 2023;158(3).

[11] Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, et al. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. *Am J Psychiatry.* 2022;179(2):98-109.

[12] Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. *BMC Med.* 2022;20(1):259.

[13] Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *Lancet Psychiatry.* 2019;6(12):995-1010.

[14] Trimbos Instituut. Cannabis als medicijn: het Medusa-onderzoek. Via:
<https://www.trimbos.nl/actueel/nieuws/cannabisals-medicijn-het-medusa-onderzoek/>. 2023.

[15] Stichting Farmaceutische Kengetallen. Verstrekkingen medicinale cannabis opnieuw minder. Pharmaceutisch Weekblad. 2022;157(12).

[16] Cairns EA, Benson MJ, Bedoya-Perez MA, Macphail SL, Mohan A, Cohen R, et al. Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Front Pharmacol. 2023;14:1142680.

[17] Batalla A, Maat A. Cannabis use and psychosis susceptibility: A call to action. Eur Neuropsychopharmacol. 2022;54:70-1.

[18] Nederlands Huisartsen Genootschap. NHG-Standpunt Cannabis. Via: <https://richtlijnen.nhg.org/download/1218/nhgstandpunt-cannabis>. 2018.